ArticleEuropean heart journal. Cardiovascular Imaging2018
Validation of 2-year 123I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure.
Article in European heart journal. Cardiovascular Imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Stratifying risk of heart failure death and arrhythmic events: a ¹²³I-meta-iodobenzylguanidine-based multinomial logistic model.European journal of nuclear medicine and molecular imaging · 2026Article
- Cardiac sympathetic activity and lethal arrhythmic events: insight into bell-shaped relationship betweenEJNMMI research · 2024Article
- J-ACCESS investigation and nuclear cardiology in Japan: implications for heart failure.Annals of nuclear medicine · 2023Review
- Seeing is believing: Visualization of multivariable risk models.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Validation of a Five-Year Prognostic Model UsingAnnals of nuclear cardiology · 2023Article
- Decreased cholinesterase level combined with renal dysfunction and sympathetic denervation associated with increased cardiac mortality in systolic heart failure.Frontiers in cardiovascular medicine · 2023Article
- Three-Dimensional Heart Segmentation and Absolute Quantitation of CardiacAnnals of nuclear cardiology · 2023Article
- Machine learning-based risk model usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Nuclear Cardiology Data Analyzed Using Machine Learning.Annals of nuclear cardiology · 2022Review
- Prognostic value of nutritional parameters in systolic heart failure with renal dysfunction.PloS one · 2022Article
- Convolutional neural network-based automatic heart segmentation and quantitation inEJNMMI research · 2021Article
- Risk stratification based on J-ACCESS risk models with myocardial perfusion imaging: Risk versus outcomes of patients with chronic kidney disease.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Article
- Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2020Article
- Risk Stratification of Sudden Cardiac Death in Patients with Heart Failure: An update.Journal of clinical medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: The aim of this study was to validate a four-parameter risk model including 123I-meta-iodobenzylguanidine (MIBG) imaging, which was previously developed for predicting cardiac mortality, in a new cohort of patients with chronic heart failure (CHF). Methods and results: Clinical and outcome data were retrospectively obtained from 546 patients (age 66 ± 14 years) who had undergone 123I-MIBG imaging with a heart-to-mediastinum ratio (HMR). The mean follow-up time was 30 ± 20 months, and the endpoint was cardiac death. The mortality outcome predicted by the model was compared with actual 2-year event rates in pre-specified risk categories of three or four risk groups using Kaplan-Meier survival analysis for cardiac death and receiver-operating characteristic (ROC) analysis. Cardiac death occurred in 137 patients, including 105 (68%) patients due to heart-failure death. With a 2-year mortality risk from the model divided into three categories of low- (<4%), intermediate- (4-12%), and high-risk (>12%), 2-year cardiac mortality was 1.1%, 7.9%, and 54.7%, respectively in the validation population (P < 0.0001). In a quartile analysis, although the predicted numbers of cardiac death was comparable with actual number of cardiac death for low- to intermediate-risk groups with a mortality risk <13.8%, it was underestimated in the high-risk group with a mortality risk ≥13.8%. The ROC analysis showed that the 2-year risk model had better (P < 0.0001) diagnostic ability for predicting heart failure death than left ventricular ejection fraction, natriuretic peptides or HMR alone. Conclusion: The 2-year risk model was successfully validated particularly in CHF patients at a low to intermediate cardiac mortality risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.